- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Fostamatinib (as the disodium hexahydrate salt) received FDA approval for the treatment of chronic immune thrombocytopenia (ITP)  in April 2018, in particular for the treatment of patients with an inadequete response to previous treatment.
Fostamatinib has completed Phase 3 clinical trials for rheumatoid arthritis  (NCT01197534 & NCT01197755), and Phase 2 for a range of solid tumours (NCT00923481).
|Mechanism Of Action and Pharmacodynamic Effects|
|The active moeity, tamatinib inhibits Syk kinase-mediated IgE- and IgG-mediated activation of Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage [1,4].|